AI-generated analysis. Always verify with the original filing.
This 10-K/A amendment for FibroBiologics, Inc. for fiscal year 2025, filed on March 13, 2026, provides updated Part III disclosures (Items 10-14) but does not contain or amend any financial statements. The amendment includes information on directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accountant fees. The document explicitly states that no financial statements are included and no previously reported financial results are changed. The company is an emerging growth company and smaller reporting company. Key executive compensation for 2025 shows CEO Pete O'Heeron received total compensation of $1,051,474, including a $617,500 salary and $394,110 in option awards. The aggregate market value of the company's voting and non-voting common equity held by non-affiliates at June 30, 2025 was $21.6 million.
This 10-K/A amendment for FibroBiologics, Inc. for fiscal year 2025, filed on March 13, 2026, is an amendment to the original 10-K filed on February 24, 2026. The amendment specifically adds Part III disclosures (Items 10-14) that were omitted from the original filing. The document explicitly states that no financial statements are included in this amendment and it does not change any previously reported financial results. The company identifies as an emerging growth company and smaller reporting company. The aggregate market value of the registrant's voting and non-voting common equity held by non-affiliates at June 30, 2025 was $21.6 million. At February 24, 2026, 67,594,722 shares of FibroBiologics, Inc.'s Common Stock were outstanding.
No revenue or segment data is provided in this amendment. The document is focused solely on corporate governance, executive compensation, and related party transaction disclosures. The amendment explicitly states that it does not modify or update disclosure in, or exhibits to, the 2025 Annual Report beyond the Part III items. The company's business model involves developing cell therapy products, but no financial performance metrics or revenue figures are disclosed in this amendment.
No profitability metrics, margins, or income statement data are provided in this amendment. The document contains only the Part III disclosures required by SEC regulations for directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accountant fees. The amendment does not contain any financial statements or discussion of financial performance, margins, or profitability measures.
No cash flow or balance sheet data is provided in this amendment. The document explicitly states that no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K. The certifications under Section 906 of the Sarbanes-Oxley Act of 2002 are not included as no financial statements are being filed with this Amendment.
The document contains forward-looking statements covering various aspects of the company's business including the timing, progress and results of preclinical studies and clinical trials, regulatory submissions and approvals, ability to develop product candidates, expectations regarding patient populations, implementation of business model and strategic plans, commercialization capabilities, pricing and reimbursement of product candidates, market acceptance, ability to establish collaborations, competitive position, intellectual property protection, industry developments, estimates regarding expenses and capital requirements, and impact of laws and regulations. The company cautions that these forward-looking statements are subject to risks and uncertainties and actual results could differ materially. No specific financial guidance or outlook is provided in this amendment.